Skip to main content
TCRT logo

Alaunos Therapeutics, Inc. (TCRT) Stock Price & Analysis

Alaunos Therapeutics, Inc. (TCRT) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $1.59 (-7.02%), as of the Nov 19, 2026 trading session; market cap $6.69M.

Educational signal · not a buy or sell recommendation · How to read this

$1.59 −$0.12 (-7.02%) Market Cap $6.69M

Alaunos Therapeutics, Inc. · TCRT · NASDAQ

Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing adoptive T-cell receptor (TCR) engineered therapies for cancer treatment. The company is advancing innovative therapies targeting various solid tumors through its proprietary technology platform.

Price as of Nov 19, 2026

Key Statistics

19 of 100

MoonshotScore v2 · Alaunos Therapeutics (TCRT)

Weak
Business Quality Poor (6)
Financial Safety Strained (39)
Valuation Bubble (8)
Growth Durability Fading (37)
Momentum Quiet (40)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet, weak growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Fading; Momentum: Quiet.

  • quarterly revenue $3,000 (Q4 FY2025, quarter ended Dec 31, 2025)
  • EPS beat 8 of the last 8 reports

Holding back: weak fundamentals, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TCRT (57 recorded, newest six shown)
RecordedScoreBand
23Weak
18Weak
18Weak
18Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.59
Change on the day-7.02%
Market capitalisation$6.69M—
Shares traded on the day90.4K

Price & events

Other perspectives

Council score for Alaunos Therapeutics (TCRT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Negative
Growth Durability Weak
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alaunos Therapeutics (TCRT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alaunos Therapeutics, Inc. (TCRT) is listed on NASDAQ. It employs 1 people. In Q4 FY2025 it reported revenue of $3,000 and net income of -$893,000. The market values it at $6.69M.

2 · Latest results

What do the latest results show for Alaunos Therapeutics (TCRT)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of $3,000. Against analyst estimates the company has EPS beat 8 of the last 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025$3,000-$893,000-$0.40 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Alaunos Therapeutics (TCRT)?

Short answer · as of

What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.77 · earnings yield -101.2% · free-cash-flow yield -50.4%.

4 · What to check next?

What should you watch next at Alaunos Therapeutics (TCRT)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $87.53M · EPS -0.20 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q4 FY2025) was filed Mar 31, 2026 — 7 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Alaunos Therapeutics compare with its peers?

Short answer

Alaunos Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.13 Nov 19, 2026$481M60 5-pillar Nov 18, 2026
Cybin Inc. (HELP) Same industry, near in market value$6.78 Nov 19, 2026$541M60 5-pillar Nov 18, 2026
Alaunos Therapeutics (TCRT) — this page$1.59$6.69M19

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$87.53M
EPS estimate
$-0.20

Measured against a quoted price of $1.59 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 6, 2026

Transactions
11
Identified insiders
4
Purchases
0
Sales
0
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TCRT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TCRT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Alaunos Therapeutics (TCRT)?

Read these with our analysis →

Alaunos Therapeutics Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the TCRT research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for TCRT?

TCRT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is TCRT a good stock to buy?

Stock Expert AI does not rate TCRT buy, sell or hold. Alaunos Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TCRT stock price today?

The last price recorded for Alaunos Therapeutics, Inc. (TCRT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for TCRT?

Alaunos Therapeutics, Inc. faces several risks, including the potential for clinical trial failures that could impede progress and funding. Regulatory hurdles may delay the approval of therapies, and the company operates in a highly competitive landscape where other biotech firms are developing similar cancer therapies.

What are the key factors to evaluate for TCRT?

Alaunos Therapeutics, Inc. (TCRT) holds a MoonshotScore in the low range. No dividend yield as the company reinvests all resources into R&D for future therapies. Not financial advice.

How frequently does TCRT data refresh on this page?

TCRT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TCRT's recent stock price performance?

Alaunos Therapeutics, Inc. (TCRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative TCR technology platform for personalized cancer therapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TCRT overvalued or undervalued right now?

Alaunos Therapeutics, Inc. (TCRT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of TCRT?

Fractional-share availability for Alaunos Therapeutics, Inc. (TCRT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.